Biocept's CNSide assay identifies HER2 and other tumor alter

Biocept's CNSide assay identifies HER2 and other tumor alterations in patients with breast cancer

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and Chief Medical Officer Dr Michael Dugan tell Proactive it presented a study demonstrating the...

Related Keywords

, Michael Dugan , Mike Nall , Biocept Inc , Chief Medical Officer Dr Michael Dugan , Spotlight Presentation , San Antonio Breast Cancer Symposium ,